98 related articles for article (PubMed ID: 9684759)
1. Fourier transform infrared (FT-IR) spectroscopic studies of peptide models for interaction of the binding regions of high molecular weight kininogen and prekallikrein.
Lin Y; Li W; Wu J; Zhang H; Colman RW
Thromb Res; 1998 Apr; 90(2):65-72. PubMed ID: 9684759
[TBL] [Abstract][Full Text] [Related]
2. Direct evidence for multifacial contacts between high molecular weight kininogen and plasma prekallikrein.
Lin Y; Shenoy SS; Harris RB; Colman RW
Biochemistry; 1996 Oct; 35(39):12945-9. PubMed ID: 8841140
[TBL] [Abstract][Full Text] [Related]
3. Physical and biological significance of peptide sequences mediating the interaction between high molecular weight kininogen and plasma prekallikrein.
Colman RW; Lin Y; Yan WY; McCrae KR; Shenoy SS; Harris RB
Immunopharmacology; 1997 Jun; 36(2-3):193-200. PubMed ID: 9228546
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation.
Hooley E; McEwan PA; Emsley J
J Thromb Haemost; 2007 Dec; 5(12):2461-6. PubMed ID: 17922805
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein.
Renné T; Gailani D; Meijers JC; Müller-Esterl W
J Biol Chem; 2002 Feb; 277(7):4892-9. PubMed ID: 11733491
[TBL] [Abstract][Full Text] [Related]
6. Solution phase conformation studies of the prekallikrein binding domain of high molecular weight kininogen.
Scarsdale JN; Harris RB
J Protein Chem; 1990 Oct; 9(5):647-59. PubMed ID: 2085389
[TBL] [Abstract][Full Text] [Related]
7. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2.
Renné T; Dedio J; Meijers JC; Chung D; Müller-Esterl W
J Biol Chem; 1999 Sep; 274(36):25777-84. PubMed ID: 10464316
[TBL] [Abstract][Full Text] [Related]
8. Structures of factor XI and prekallikrein bound to domain 6 of high-molecular weight kininogen reveal alternate domain 6 conformations and exosites.
Li C; Barroeta AB; Wong SS; Kim HJ; Pathak M; Dreveny I; Meijers JCM; Emsley J
J Thromb Haemost; 2023 Sep; 21(9):2378-2389. PubMed ID: 37068593
[TBL] [Abstract][Full Text] [Related]
9. Mapping of the high molecular weight kininogen binding site of prekallikrein. Evidence for a discontinuous epitope formed by distinct segments of the prekallikrein heavy chain.
Herwald H; Jahnen-Dechent W; Alla SA; Hock J; Bouma BN; Müller-Esterl W
J Biol Chem; 1993 Jul; 268(19):14527-35. PubMed ID: 7686159
[TBL] [Abstract][Full Text] [Related]
10. Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix.
Motta G; Shariat-Madar Z; Mahdi F; Sampaio CA; Schmaier AH
Thromb Haemost; 2001 Sep; 86(3):840-7. PubMed ID: 11583317
[TBL] [Abstract][Full Text] [Related]
11. Calorimetric and spectroscopic examination of the solution phase structures of prekallikrein binding domain peptides of high molecular weight kininogen.
You JL; Scarsdale JN; Harris RB
J Protein Chem; 1991 Jun; 10(3):301-11. PubMed ID: 1910462
[TBL] [Abstract][Full Text] [Related]
12. Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain.
Page JD; You JL; Harris RB; Colman RW
Arch Biochem Biophys; 1994 Oct; 314(1):159-64. PubMed ID: 7944388
[TBL] [Abstract][Full Text] [Related]
13. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.
Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW
Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169
[TBL] [Abstract][Full Text] [Related]
14. Conformational analysis of synthetic peptides encompassing the factor XI and prekallikrein overlapping binding domains of high molecular weight kininogen.
You JL; Page JD; Scarsdale JN; Colman RW; Harris RB
Peptides; 1993; 14(5):867-76. PubMed ID: 8284263
[TBL] [Abstract][Full Text] [Related]
15. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor.
Joseph K; Tholanikunnel BG; Kaplan AP
J Allergy Clin Immunol; 2009 Jul; 124(1):143-9. PubMed ID: 19342086
[TBL] [Abstract][Full Text] [Related]
16. FT-IR spectroscopy indicates that Ca(2+)-binding to phosphorylated C-terminal fragments of the midsized neurofilament protein subunit results in beta-sheet formation and beta-aggregation.
Holly S; Laczkó I; Fasman GD; Hollósi M
Biochem Biophys Res Commun; 1993 Dec; 197(2):755-62. PubMed ID: 8267612
[TBL] [Abstract][Full Text] [Related]
17. Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2.
Renné T; Sugiyama A; Gailani D; Jahnen-Dechent W; Walter U; Müller-Esterl W
Int Immunopharmacol; 2002 Dec; 2(13-14):1867-73. PubMed ID: 12489801
[TBL] [Abstract][Full Text] [Related]
18. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4.
Herwald H; Renné T; Meijers JC; Chung DW; Page JD; Colman RW; Müller-Esterl W
J Biol Chem; 1996 May; 271(22):13061-7. PubMed ID: 8662705
[TBL] [Abstract][Full Text] [Related]
19. Zinc-dependent conformational changes in domain D5 of high molecular mass kininogen modulate contact activation.
Herwald H; Mörgelin M; Svensson HG; Sjöbring U
Eur J Biochem; 2001 Jan; 268(2):396-404. PubMed ID: 11168375
[TBL] [Abstract][Full Text] [Related]
20. Binding of high-molecular-mass kininogen to the Apple 1 domain of factor XI is mediated in part by Val64 and Ile77.
Seaman FS; Baglia FA; Gurr JA; Jameson BA; Walsh PN
Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):715-21. PubMed ID: 7818472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
